Obesity, aging and longevity ETFs in the biology trade

Makers of obesity drugs and companies serving older people. Driven by obesity drug sales and trial results, and spending on older people's care.

4ETFs in this category

$158mmoney in them

0.1%of the biology trade’s money

AGNGlargest unleveraged ETF, 60.6%

How they did, to Nov 2, 2026

	1 month	YTD	12 months
Category median	+6.1%	+2.9%	+14.9%
Its story	+7.5%	+21.0%	+29.0%
Broad US ETFs	−2.5%	+11.5%	+11.8%

1 month

YTD

12 months

Category median

+6.1%

+2.9%

+14.9%

Its story

+7.5%

+21.0%

+29.0%

Broad US ETFs

−2.5%

+11.5%

+11.8%

Every ETF here, largest first

#	ETF	Name	Assets	Share	12 months	Fee
1	AGNG	Global X Aging Population ETF	$95m	60.6%	+18.7%	0.50%
2	OZEM	Roundhill GLP-1 & Weight Loss ETF	$56m	35.2%	+7.7%	0.59%
3	THNR	Amplify Weight Loss Drug & Treatment ETF	$6m	3.6%	+14.9%	0.59%
4	YUNG	Corgi Longevity Consumer ETF	under $1m	0.6%	–	0.35%

Other categories in the biology trade

Broad health care 18 ETFs Biotech 8 ETFs Devices and providers 3 ETFs Genomics and health innovation 13 ETFs Pharmaceuticals 6 ETFs Leveraged and inverse 20 ETFs Everything else 10 ETFs

Common questions

Which ETFs are obesity, aging and longevity ETFs?4 US ETFs sit in this category of the biology trade. Makers of obesity drugs and companies serving older people. Driven by obesity drug sales and trial results, and spending on older people's care.

What is the largest obesity, aging and longevity ETF?AGNG, Global X Aging Population ETF, with $95m, 60.6% of the category's money.

How have obesity, aging and longevity ETFs performed?The median unleveraged ETF here returned +14.9% over the last 12 months to Nov 2, 2026, against +11.8% for broad US ETFs. Past performance, not a forecast.